![9-[(2R,3S,5S)-3-Fluoro-5-(Hydroxymethyl)Oxolan-2-Yl]-3H-Purin-6-One](https://static.cymitquimica.com/products/3D/img/FF98319.png "Clique para ampliar")
9-[(2R,3S,5S)-3-Fluoro-5-(Hydroxymethyl)Oxolan-2-Yl]-3H-Purin-6-One
CAS: 117525-25-4
Ref. 3D-FF98319
| Tamanho indefinido | A consultar |
Informação sobre produto
- 2'-F-dd-Aral
- 6H-Purin-6-one, 9-(2,3-dideoxy-2-fluoro-beta-D-threo-pentofuranosyl)-1,9-dihydro-
- 9-(2,3-dideoxy-2-fluoro-beta-D-threo-pentofuranosyl)-3,9-dihydro-6H-purin-6-one
9-[(2R,3S,5S)-3-Fluoro-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one (FHA) is a prodrug that contains a hydroxymethyl group. FHA can be hydrolyzed by the enzyme aldehyde oxidase to form 9-[(2R,3S,5S)-3-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one (FAU). FAU is more potent than FHA and has been shown to inhibit HIV replication in cell culture. FHA was administered to humans and its pharmacokinetic properties were studied. The plasma concentration of FHA increased with time after administration and reached a maximum level at about 3 hours. The maximum concentration of FAU was found at about 1 hour. The elimination half life of both compounds was approximately 2 hours. The workstation architecture used
Propriedades químicas
Consulta técnica sobre: 3D-FF98319 9-[(2R,3S,5S)-3-Fluoro-5-(Hydroxymethyl)Oxolan-2-Yl]-3H-Purin-6-One
Se desejar solicitar um orçamento ou fazer uma encomenda, por favor, adicione os produtos ao seu carrinho e depois solicite um orçamento ou encomenda a partir do carrinho. É mais rápido, mais barato e poderá beneficiar-se dos descontos e outras vantagens disponíveis.
